Citations

Showing 10 of 108094 citations.

The genetic landscape of autosomal dominant polycystic kidney disease in Kuwait
Ali, Hamad , Naim, Medhat, Senum, Sarah R. , AlSahow, Ali , Bahbahani, Yousif , Abu‐Farha, Mohamed , Al‐Hunayan, Adel, Zayed, Mohamed A. , Hussain, Naser, John, Sumi Elsa , Channanath, Arshad, Al-Ali, Mohammad, Al-Mousawi, M, Harris, Peter C. , Harris, Peter C , Senum, Sarah R , Abubaker, Jehad Ahmed , Mohammad, Anwar , Asbeutah, Akram Mahmoud , Zayed, Mohamed, Devarajan, Sriraman , Thanaraj, Thangavel Alphonse , Al‐Mulla, Fahd

Mayo Clinic

Clinical Kidney Journal | October 29, 2022 | Volume: 16 | Issue: 2 | Pages: 355-366

10.1093/ckj/sfac236 | PMID 36755831 Get It

ABSTRACT Background Autosomal dominant polycystic kidney disease (ADPKD) is the most common renal monogenic disease, characterized by bilateral accumulation of renal fluid-filled cysts leading to progressive renal volume enlargement and gradual impairment of kidney function, often resulting in end-stage renal disease. Kuwait could provide valuable genetic insights about ADPKD, including intrafamilial phenotypic variation, given its large household size. This study aims to provide a comprehensive description of the pathogenic variants linked to ADPKD in the Kuwaiti population using multiple genetic analysis modalities and to describe and analyse the ADPKD phenotypic spectrum in terms of kidney function, kidney volume and renal survival. Methods A total of 126 ADPKD patients from 11 multiplex families and 25 singletons were recruited into the study. A combination of targeted next-generation sequencing (tNGS), long-range polymerase chain reaction, Sanger sequencing and multiplex ligation-dependent probe amplification were utilized for genetic diagnosis. Clinical evaluation was conducted through renal function testing and ultrasonographic kidney volume analysis. Results We identified 29 ADPKD pathogenic mutations from 36 families achieving an overall molecular genetic diagnostic rate of 112/126 (88.9%), including 29/36 (80.6%) in families. A total of 28/36 (77.8%) families had pathogenic mutations in PKD1, of which 17/28 (60.7%) were truncating, and 1/36 (2.8%) had a pathogenic variant in the IFT140 gene. A total of 20/29 (69%) of the identified ADPKD mutations were novel and described for the first time, including a TSC2-PKD1 contiguous syndrome. Clinical analysis indicated that genetically unresolved ADPKD cases had no apparent association between kidney volume and age. Conclusion We describe for the first time the genetic landscape of ADPKD in Kuwait. The observed genetic heterogeneity underlining ADPKD along with the wide phenotypic spectrum reveal the level of complexity in disease pathophysiology. ADPKD genetic testing could improve the care of patients through improved disease prognostication, guided treatment and genetic counselling. However, to fulfil the potential of genetic testing, it is important to overcome the hurdle of genetically unresolved ADPKD cases.
Factors Associated With COVID-19 Non-vaccination in Adolescents Hospitalized Without COVID-19
Price, Ashley M. , Newhams, Margaret M. , Halasa, Natasha , Bline, Katherine , Cameron, Melissa A. , Walker, Tracie C. , Irby, Katherine , Nofziger, Ryan A. , Mack, Elizabeth H. , Smallcomb, Laura , Bradford, Tamara T. , Kamidani, Satoshi , Tarquinio, Keiko M. , Schuster, Jennifer E. , Bhumbra, Samina S. , Levy, Emily R. , Cullimore, Melissa L. , Coates, Bria M. , Heidemann, Sabrina M. , Gertz, Shira J. , Kong, Michele , Flori, Heidi R. , Staat, Mary Allen , Zinter, Matt S. , Hume, Janet R. , Chatani, Brandon , Gaspers, Mary Glas , Maamari, Mia , Randolph, Adrienne G. , Patel, Manish , Boom, Julie A. , Kamidani, Satoshi , Hobbs, Charlotte V , Heidemann, Sabrina , Levy, Emily R , Randolph, Adrienne G , Kong, Michele , Hume, Janet R , Staat, Mary A , Gertz, Shira J , Bline, Katherine E , Sahni, Leila C , Olson, Samantha M. , Pannaraj, Pia S. , Maddux, Aline B. , Schwartz, Stephanie P. , Chiotos, Kathleen , Cvijanovich, Natalie Z , Hobbs, Charlotte V.

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | October 28, 2022 | Volume: 12 | Issue: 1 | Pages: 29-35

10.1093/jpids/piac113 | PMID 36309873 Get It

Abstract Background Pfizer-BioNTech COVID-19 vaccine received emergency use authorization for persons ≥ 16 years in December 2020 and for adolescents 12–15 years in May 2021. Despite the clear benefits and favorable safety profile, vaccine uptake in adolescents has been suboptimal. We sought to assess factors associated with COVID-19 non-vaccination in adolescents 12–18 years of age. Methods Between June 1, 2021 and April 29, 2022, we assessed factors associated with COVID-19 non-vaccination in hospitalized adolescents ages 12–18 years enrolled in the Overcoming COVID-19 vaccine effectiveness network. Demographic characteristics and clinical information were captured through parent interviews and/or electronic medical record abstraction; COVID-19 vaccination was assessed through documented sources. We assessed associations between receipt of the COVID-19 vaccine and demographic and clinical factors using univariate and multivariable logistic regression and estimated adjusted odds ratios (aOR) for each factor associated with non-vaccination. Results Among 1665 hospitalized adolescents without COVID-19, 56% were unvaccinated. Unvaccinated adolescents were younger (median age 15.1 years vs. 15.4 years, p < .01) and resided in areas with higher social vulnerability index (SVI) scores (median 0.6 vs 0.5, p < .001) than vaccinated adolescents. Residence in the Midwest [aOR 2.60 (95% CI: 1.80, 3.79)] or South [aOR 2.49 (95% CI: 1.77, 3.54)] US census regions, rarely or never receiving influenza vaccine [aOR 5.31 (95% CI: 3.81, 7.47)], and rarely or never taking precautions against COVID-19 [aOR 3.17 (95% CI: 1.94, 5.31)] were associated with non-vaccination against COVID-19. Conclusions Efforts to increase COVID-19 vaccination of adolescents should focus on persons with geographic, socioeconomic, and medical risk factors associated with non-vaccination.
Can CSF Biomarkers Decode Contributions of Combined Aβ Plaque, Tau Tangle, and α-Synuclein Pathology?
Knopman, David S.

Mayo Clinic

Neurology | October 28, 2022 | Volume: 99 | Issue: 20 | Pages: 877-878

10.1212/wnl.0000000000201287 | PMID 36307221 Get It

CRISTAL Clear Results: Enoxaparin or Aspirin for Venous Thromboembolism Prevention After Hip and Knee Arthroplasties
Houghton, Damon E. , Wyles, Cody C.

Mayo Clinic

The Hematologist | October 28, 2022 | Volume: 19 | Issue: 6 | Pages: No page available

10.1182/hem.v19.6.202264 Get It

Minocycline‐induced hyperpigmentation in a patient on long‐term Nocardia suppressive treatment
Baqal, Omar , Masson, Rajeev , Hardaway, Brian , Hardaway, Brian W, Baqal, Omar J

Mayo Clinic

Transplant Infectious Disease | October 28, 2022 | Volume: 24 | Issue: 6 | Pages: No page available

10.1111/tid.13980 | PMID 36306192 Get It

Faculty Opinions recommendation of Percutaneous revascularization for ischemic left ventricular dysfunction.
Gersh, Bernard J.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 28, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742294233.793596168 Get It

Future proofing medical education: The case for a confrontationally oriented and hidden curriculum informed restructuring of professional preparation
Hafferty, Frederic W.

Mayo Clinic

The Clinical Teacher | October 28, 2022 | Volume: 19 | Issue: S2 | Pages: No page available

10.1111/tct.13537 Get It

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
Desai, Sanjal H. , Mwangi, Raphael , Smith, Alexandra N., King, Rebecca L. , Thompson, Carrie A. , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A , Wang, Yucai , Witzig, T.E. , Desai, Sanjal , Maurer, Matthew J. , Farooq, Umar , Cerhan, James R. , Feldman, Andrew L. , Habermann, Thomas M. , Wang, Yucai , Witzig, Thomas E.

Mayo Clinic

Hematological Oncology | October 28, 2022 | Volume: 41 | Issue: 1 | Pages: 39-49

10.1002/hon.3098 | PMID 36305717 Get It

Abstract Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R‐CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well‐characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non‐GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI 95 : 38–54] vs. non‐GCB: 44% [CI 95 :36–55], p > 0.05) or GEP (2 years OS ABC: 42% [CI 95 : 29–59] vs. GCB: 40% [CI 95 : 30–54], p > 0.05), was not associated with difference in OS. DHL (2 years OS 16 [CI 95 :6–45] vs. 45% [CI 95 : 34–59], p < 0.01) and DEL (2 years OS 33% [CI 95 : 20–56], vs. 50% [CI 95 : 41–60], p < 0.05) had lower OS than non‐DHL and non‐DEL/non‐DHL counterparts, respectively. COO by IHC or GEP was not associated with OS in R/R DLBCL while DHL and DEL were adverse prognostic markers in DLBCL at first relapse.
A Randomized Pilot Study of Online Hatha Yoga for Physical and Psychological Symptoms Among Survivors of Allogenic Bone Marrow Transplant
Eckert, Ryan , Huberty, Jennifer , Kurka, Jonathan , Palmer, Jeanne , Huberty, Jennifer , Laird, Breanne , Mesa, Ruben A.

Mayo Clinic

International Journal of Yoga Therapy | October 28, 2022 | Volume: 32 | Issue: 2022 | Pages: No page available

10.17761/2022-d-21-00047 | PMID 36305845 Get It

Abstract Bone marrow transplant (BMT) is a curative procedure for patients with hematological malignancies, hemoglobinopathies, and errors of inborn metabolism. Survivors are not without symptom burden. The purpose of this study was to assess the feasibility of a 12-week online yoga intervention compared to an educational control group in survivors of allogenic BMT. Participants were recruited nationally. Consenting participants were assigned to online yoga or a podcast control. Yoga and control group participants were instructed to complete 12 weeks of 60 minutes/week of online yoga and podcasts, respectively. Study participants were asked to complete online questionnaires at baseline (wk 0), midpoint (wk 6), postintervention (wk 12), and follow-up (wk 20). Feasibility benchmarks included &gt; 70% satisfied with intervention and &gt; 70% intending to continue participating in online yoga (acceptability); &gt; 70% of participants achieving &gt; 42 minutes/week of online yoga (demand); &gt; 70% completing all four questionnaires (practicality); and at least small effect sizes of the intervention on Lee Symptom Score, physical function, fatigue, anxiety, sleep disturbance, social functioning, pain interference, depression, and quality of life as compared to control group (limited efficacy). Seventy-two participants consented and enrolled in the study (yoga group n = 33; podcast group n = 39). Of the yoga group participants, 54.5% (n = 19) completed the postintervention questionnaire, with 73.7% (n = 14) indicating they were satisfied/very satisfied and 15.8% (n = 3) likely/very likely to continue online yoga. Yoga participation averaged 31.98 minutes/week across 12 weeks. Both groups experienced a significant improvement in the Lee Symptom Score (6.2%–8.7% improvement from baseline) and depressive symptoms (5.3%–6.6% improvement from baseline). The yoga group experienced a significant reduction in pain (6.1% from baseline), and the podcast group experienced a significant reduction in fatigue (6.4% improvement from baseline). Online yoga was not found to be feasible to deliver to this population of survivors of BMT. However, there was satisfaction with online yoga among the majority of survivors of BMT, and beneficial effects were experienced in the yoga group on Lee Symptom Score, depressive symptoms, and pain. Future research is needed to enhance our understanding of barriers to online yoga participation for survivors of BMT and to determine its efficacy.
Development of new postoperative neck pain at 12 and 24 months after surgery for cervical spondylotic myelopathy: a Quality Outcomes Database study
Sherrod, Brandon A. , Michalopoulos, Giorgos D. , Mulvaney, Graham , Agarwal, Nitin , Chan, Andrew K. , Asher, Anthony L. , Coric, Domagoj , Virk, Michael S. , Fu, Kai-Ming, Foley, Kevin T. , Park, Paul , Upadhyaya, Cheerag D., Knightly, John J. , Shaffrey, Mark E., Potts, Eric A. , Shaffrey, Christopher I. , Gottfried, Oren N., Than, Khoi D. , Wang, Michael Y. , Tumialán, Luis M. , Chou, Dean , Mummaneni, Praveen V. , Bydon, Mohamad , Bisson, Erica F. , Michalopoulos, Giorgos

Mayo Clinic

Journal of Neurosurgery: Spine | October 28, 2022 | Volume: 38 | Issue: 3 | Pages: 357-365

10.3171/2022.9.spine22611 | PMID 36308471 Get It

OBJECTIVE Patients who undergo surgery for cervical spondylotic myelopathy (CSM) will occasionally develop postoperative neck pain that was not present preoperatively, yet the incidence of this phenomenon is unclear. The authors aimed to elucidate patient and surgical factors associated with new-onset sustained pain after CSM surgery. METHODS The authors reviewed data from the Quality Outcomes Database (QOD) CSM module. The presence of neck pain was defined using the neck pain numeric rating scale (NRS). Patients with no neck pain at baseline (neck NRS score ≤ 1) were then stratified based on the presence of new postoperative pain development (neck NRS score ≥ 2) at 12 and 24 months postoperatively. RESULTS Of 1141 patients in the CSM QOD, 224 (19.6%) reported no neck pain at baseline. Among 170 patients with no baseline neck pain and available 12-month follow-up, 46 (27.1%) reported new postoperative pain. Among 184 patients with no baseline neck pain and available 24-month follow-up, 53 (28.8%) reported new postoperative pain. The mean differences in neck NRS scores were 4.3 for those with new postoperative pain compared with those without at 12 months (4.4 ± 2.2 vs 0.1 ± 0.3, p < 0.001) and 3.9 at 24 months (4.1 ± 2.4 vs 0.2 ± 0.4, p < 0.001). The majority of patients reporting new-onset neck pain reported being satisfied with surgery, but their satisfaction was significantly lower compared with patients without pain at the 12-month (66.7% vs 94.3%, p < 0.001) and 24-month (65.4% vs 90.8%, p < 0.001) follow-ups. The baseline Neck Disability Index (NDI) was an independent predictor of new postoperative neck pain at both the 12-month and 24-month time points (adjusted OR [aOR] 1.04, 95% CI 1.01–1.06; p = 0.002; and aOR 1.03, 95% CI 1.01–1.05; p = 0.026, respectively). The total number of levels treated was associated with new-onset neck pain at 12 months (aOR 1.34, 95% CI 1.09–1.64; p = 0.005), and duration of symptoms more than 3 months was a predictor of 24-month neck pain (aOR 3.22, 95% CI 1.01–10.22; p = 0.048). CONCLUSIONS Increased NDI at baseline, number of levels treated surgically, and duration of symptoms longer than 3 months preoperatively correlate positively with the risk of new-onset neck pain following CSM surgery. The majority of patients with new-onset neck pain still report satisfaction from surgery, suggesting that the risk of new-onset neck pain should not hinder indicated operations from being performed.